Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01231906 : Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
PhasePhase 3
AgesMin: N/A Max: 50 Years
Eligibility
DISEASE CHARACTERISTICS:

- Newly diagnosed extracranial, non-metastatic Ewing sarcoma or primitive
neuroectodermal tumors of bone or soft tissue

- For the purpose of this study, any of the following are considered localized
disease:

- Chest wall tumors with ipsilateral pleural effusions

- Ipsilateral positive pleural fluid cytology

- Ipsilateral pleural-based secondary tumor nodules

- Regional node involvement, based on clinical suspicion confirmed by pathologic
documentation, are considered to be non-metastatic disease

- Tumors arising in the bony skull (extra-dural) are considered to be extracranial

- No evidence of metastatic disease, including the following:

- Lesions that are discontinuous from the primary tumor, are not regional lymph
nodes, and do not share a body cavity with the primary tumor

- Contralateral pleural effusion and contralateral pleural nodules

- Distant lymph node involvement

- Pulmonary nodules that meet the following criteria:

- Solitary nodule > 0.5 cm or multiple nodules of > 0.3 cm unless biopsied
and negative for Ewing sarcoma

- Biopsies of solitary nodule < 0.5 cm or multiple nodules < 3.0 cm (are not
required but if performed) positive for metastatic disease

- No tumors arising in the intra-dural soft tissue

PATIENT CHARACTERISTICS:

- Creatinine clearance or radioisotope GFR ? 70 mL/min OR serum creatinine based on age
and/or gender as follows:

- 0.4 mg/dL (1 month to < 6 months of age)

- 0.5 mg/dL (6 months to < 1 year of age)

- 0.6 mg/dL (1 year to < 2 years of age)

- 0.8 mg/dL (2 years to < 6 years of age)

- 1.0 mg/dL (6 years to < 10 years of age)

- 1.2 mg/dL (10 years to < 13 years of age)

- 1.5 mg/dL (male) or 1.4 mg/dL (female) (13 years to < 16 years of age)

- 1.7 mg/dL (male) or 1.4 mg/dL (female) (? 16 years of age)

- Total bilirubin < 1.5 times upper limit of normal (ULN)

- AST or ALT < 2.5 times ULN

- Shortening fraction of ? 27% by echocardiogram OR ejection fraction ? 50% by
radionuclide angiogram

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception for the duration of study treatment

PRIOR CONCURRENT THERAPY:

- No prior chemotherapy or radiotherapy

- Prior biopsy of the primary tumor without an attempt at complete or partial resection
allowed

- Patients are still allowed if unplanned excision was attempted or accomplished
as long as adequate imaging was obtained prior to surgery

- No other concurrent chemotherapy or immunomodulating agents (including steroids
unless used as an antiemetic)

- No concurrent sargramostim (GM-CSF)
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01231906      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740